Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Raltegravir Potassium

FDA-approved product (tablet, oral), marketed as Isentress, Isentress Hd, Raltegravir Potassium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Raltegravir Potassium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Integrase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AJ01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Raltegravir Potassium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-9.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Raltegravir Potassium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.

    NCT04258475 · start 2020-12-09

    Registered record
    Registry ID
    NCT04258475
    Conditions
    Calcium Supplementation in HIV Patients Using Raltegravir
    Interventions
    Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily.; Calcium carbonate antacid tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-12-09
    Completion
    2025-01-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCalcium Supplementation in HIV Patients Using Raltegravir
    InterventionRaltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily.; Calcium carbonate antacid tablet
    PhasePhase 4
    Registry statusUnknown

  • ARTiBIOME: Observational Study on the Effect of HIV and ART on Gut Microbiome

    NCT04460924 · start 2020-11-01

    Registered record
    Registry ID
    NCT04460924
    Conditions
    HIV Infections
    Interventions
    Integrase strand transfer inhibitors
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-11-01
    Completion
    2023-03-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIntegrase strand transfer inhibitors
    PhaseNot recorded
    Registry statusCompleted

  • Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study

    NCT03842488 · start 2019-04

    Registered record
    Registry ID
    NCT03842488
    Conditions
    HIV Infections
    Interventions
    Experimental: RAL QD; Active comparator: DRV/cb
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-04
    Completion
    2021-03
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionExperimental: RAL QD; Active comparator: DRV/cb
    PhasePhase 4
    Registry statusUnknown

  • Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir

    NCT03374358 · start 2018-01-10

    Registered record
    Registry ID
    NCT03374358
    Conditions
    HIV Seropositivity; Metabolic Syndrome; Fatty Liver
    Interventions
    Raltegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-01-10
    Completion
    2019-11-30
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Seropositivity; Metabolic Syndrome; Fatty Liver
    InterventionRaltegravir
    PhasePhase 4
    Registry statusCompleted

  • Dual Therapy Etravirine + Raltegravir by Once Daily in HIV-positive Patients (ETRAL QD)

    NCT03369743 · start 2018-01-02

    Registered record
    Registry ID
    NCT03369743
    Conditions
    HIV Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-01-02
    Completion
    2019-12-30
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

    NCT03256422 · start 2017-09-07

    Registered record
    Registry ID
    NCT03256422
    Conditions
    HIV Infections
    Interventions
    Treatment discontinuation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-07
    Completion
    2020-03-02
    Enrolment
    640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTreatment discontinuation
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

    NCT02616029 · start 2015-12-17

    Registered record
    Registry ID
    NCT02616029
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-12-17
    Completion
    2019-07-11
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

    NCT02605954 · start 2015-11-18

    Registered record
    Registry ID
    NCT02605954
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-18
    Completion
    2018-01-24
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    PhasePhase 3
    Registry statusCompleted

  • The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)

    NCT02473367 · start 2015-06-23

    Registered record
    Registry ID
    NCT02473367
    Conditions
    HIV Infection
    Interventions
    Raltegravir 1200 mg; TUMS; Leader Antacid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-06-23
    Completion
    2015-10-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionRaltegravir 1200 mg; TUMS; Leader Antacid
    PhasePhase 1
    Registry statusCompleted

  • Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection

    NCT01854762 · start 2015-06-01

    Registered record
    Registry ID
    NCT01854762
    Conditions
    HIV; Pregnancy
    Interventions
    Raltegravir; Lopinavir/Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2015-06-01
    Completion
    2017-08-02
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Pregnancy
    InterventionRaltegravir; Lopinavir/Ritonavir
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Comprehensive HIV Prevention Package for MSM in Port Elizabeth

    NCT02449733 · start 2015-05

    Registered record
    Registry ID
    NCT02449733
    Conditions
    HIV
    Interventions
    Condom choices; Condom-compatible lubricant choices; Couples HIV counseling and testing (CVCT); Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF); HIV Testing; Linkage to care; Post-exposure prophylaxis (PEP); Risk-reduction counseling
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-05
    Completion
    2017-03
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionCondom choices; Condom-compatible lubricant choices; Couples HIV counseling and testing (CVCT); Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Renal Integrase Study

    NCT02351908 · start 2015-03

    Registered record
    Registry ID
    NCT02351908
    Conditions
    HIV
    Interventions
    Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat); Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet; Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-03
    Completion
    2017-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionStribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat); Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet; Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
    PhasePhase 4
    Registry statusCompleted

  • Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

    NCT02858401 · start 2015-01-29

    Registered record
    Registry ID
    NCT02858401
    Conditions
    HIV-1 Infection
    Interventions
    Vesatolimod; Placebo; ARV regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-01-29
    Completion
    2019-02-14
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionVesatolimod; Placebo; ARV regimen
    PhasePhase 1
    Registry statusCompleted

  • Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

    NCT02140255 · start 2015-01-23

    Registered record
    Registry ID
    NCT02140255
    Conditions
    HIV Infection
    Interventions
    Nucleoside Reverse Transcriptase Inhibitors (NRTIs); Nevirapine (NVP); Lopinavir/Ritonavir (LPV/r); Raltegravir (RAL); VRC01; Dolutegravir (DTG); VRC07-523LS
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2015-01-23
    Completion
    2031-12-31
    Enrolment
    1,120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionNucleoside Reverse Transcriptase Inhibitors (NRTIs); Nevirapine (NVP); Lopinavir/Ritonavir (LPV/r); Raltegravir (RAL) +3 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

    NCT02247687 · start 2014-12

    Registered record
    Registry ID
    NCT02247687
    Conditions
    HIV-1 Infection; Treatment Resistant Disorders; Viremia
    Interventions
    Protease inhibitor; Isentress® (raltegravir); Counseling arm
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2014-12
    Completion
    2015-09
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection; Treatment Resistant Disorders; Viremia
    InterventionProtease inhibitor; Isentress® (raltegravir); Counseling arm
    PhasePhase 3
    Registry statusTerminated